who we are

Angion is a clinical stage biopharmaceutical company
focused on acute kidney injury, a potentially life-threatening
condition without therapeutic options.

clinical trials

If you wish to learn more about enrolling in our Phase 3 trial studying the safety and efficacy of ANG-3777

OUR LEAD CLINICAL ASSET

ANG-3777

is engineered to activate the HGF/c-MET pathway,
an important mechanism in organ repair.

THE SCIENCE BEHIND

ANG-3777

ANG-3777 is engineered to mimic the biological activity of HGF in order to address the timing mismatch of HGF levels and c-MET availability, which may activate this important repair pathway subsequently promoting tissue repair and possible improved organ function.*

*ANG-3777 is currently being studied in clinical trials to determine if it is safe and effective. It is not yet approved for use by any regulatory agency globally.